Rethinking Buffer Management Through Integrated Downstream Processing

Buffer preparation is one of those parts of downstream processing that has traditionally been treated as a given. Buffers must be prepared, stored, and available when the purification process needs them, and facilities have long been designed around that requirement. But as biomanufacturing has scaled up, the amount of space, equipment and labor devoted to buffer preparation has grown with it. 

That was the starting point for a recent podcast discussion with Sébastien Lefebvre, Vice President R&D at VERDOT, and Nainesh Shah, Senior Application Engineer at Asahi Kasei Bioprocess. The two companies collaborated on a study looking at what happens when inline buffer formulation is connected directly with chromatography, using Asahi Kasei Bioprocess’ MOTIV® Inline Buffer Formulation System together with VERDOT’s FlexiPro™ Chrom platform. 

The work is described in more detail in the white paper, Transform Downstream Processing with an Integrated Solution: Optimize Time, Space and Cost Using MOTIV® Inline Buffer Formulation with FlexiPro™ Chrom.

For Lefebvre, the collaboration grew out of something he had seen firsthand while visiting a customer planning a new downstream processing facility. The chromatography equipment itself occupied only a relatively small portion of the installation. Buffer preparation required much more space and, just as importantly, much more manpower. That observation led to a broader question about whether buffer preparation and chromatography really needed to operate as separate activities. 

“The starting question was very simple,” Lefebvre said. “How can we do better by working together?” 

Buffer Demand Has Changed

Shah pointed out that the role of buffer preparation has changed as biomanufacturing has grown. Earlier processes often relied on a relatively limited number of established buffers and smaller production batches. Today, he said, a single manufacturing batch can require 50,000 to 60,000 liters of buffer. Keeping up with that demand using a conventional approach can mean expanding tank farms, adding equipment and devoting more people to preparing, cleaning, testing and managing buffers. 

Inline formulation changes that equation. Instead of preparing every finished buffer in advance, facilities prepare concentrated stock solutions that can be blended into the required formulation when the process needs them. Shah described the shift as moving toward treating buffer generation more like a manufacturing utility. 

“It’s a game changer, and looking at it as a utility more makes sense,” he said. 

Lefebvre made an important distinction during the conversation. Inline formulation does not eliminate buffer preparation. Concentrated stock solutions still need to be made and stored. What changes is the complexity of that preparation. Rather than asking operators to prepare a series of finished buffers with the correct combinations of salts, buffering components and other ingredients, facilities can prepare simpler concentrates and let the system handle the final formulation. 

“The real benefit is not the elimination of the preparation but simplification,” Lefebvre said. “You move the complexity from manual preparation to an automated system.” 

That matters because buffer preparation has traditionally depended heavily on experienced operators. Even with well-trained staff, mistakes can happen, and they may not be caught until the buffer reaches quality control. By that point, correcting the problem can mean lost time, additional work and, in some cases, delays to the downstream process. Lefebvre sees advances in analytics and process control as a way to move more of that work into an automated and controlled environment. 

Letting Chromatography Drive Buffer Production

The most interesting part of the collaboration comes from linking buffer formulation directly with chromatography. In the setup evaluated by VERDOT and Asahi Kasei Bioprocess, FlexiPro Chrom communicates the actual buffer demand to the MOTIV system in real time. Instead of preparing buffer based solely on a forecast of what the chromatography step is expected to use, the formulation system can respond to what the process is actually consuming. 

Shah sees that kind of interoperability as part of a broader change in bioprocessing. Manufacturers increasingly want to choose the equipment that works best for each part of the process, even when those systems come from different suppliers. The important thing is to make sure they can communicate. 

“They will buy the best and then make sure that they talk to each other,” Shah said. 

In this case, the systems communicate through OPC UA, allowing information to move between equipment from different suppliers in real time. Shah noted that the same principle can extend beyond this particular application. As more systems become connected, information from multiple skids can be brought into a central control environment rather than requiring an operator to monitor every piece of equipment independently. 

In the insulin case study discussed in the white paper, the team evaluated nine buffers used across capture and polishing steps. With conventional preparation, the model assumed that the full volume of each buffer would be made in advance, along with an additional safety margin of about 10%, so the chromatography system would not run short. 

With the integrated approach, buffer production could instead follow actual chromatography demand. The model still included realistic losses, including a 90-second transition period as conditions changed and a small residual volume left at the end of the step. Even with those assumptions, modeled buffer losses dropped from roughly 596 liters to 293 liters per batch, a reduction of about 51%. 

“The important point is that the benefit comes from the communication between the two systems,” Lefebvre said. “It allows us to replace a fixed safety margin with real-time information about what the chromatography process actually needs.” 

Looking at the Cost of Operating the Process

The study also considered a question that comes up frequently in established facilities: why replace a tank farm that has already been paid for? 

Lefebvre argued that the better question is what it costs to continue operating it. Even fully depreciated tanks still require people, cleaning, water, chemicals, quality control, maintenance and floor space. They can also generate waste and create delays when a buffer fails specification or equipment is unavailable. In the model discussed during the interview, those operating costs were enough to produce an estimated payback period of about 1.6 years, even when the integrated approach was compared with a fully amortized tank farm. 

“The discussion is not really about replacing old equipment with new equipment,” Lefebvre said. “It’s about whether that process is the most efficient way to operate the plant.” 

Shah added that there are plenty of costs around a tank farm that may not stand out until they are considered together. Tanks, pumps, and instruments require preventive maintenance and calibration. Facilities may have inspection requirements to meet, and production can be held up while buffers are tested and released. If a buffer is out of specification, the impact can extend well beyond the cost of remaking it. 

The business case also looks different depending on whether the facility is new or already operating. In a greenfield facility, inline formulation can reduce the need for large tanks, piping and the building space required to house them. In an existing facility, the value is more likely to come from lower operating costs: less operator time, less cleaning, lower water and chemical consumption, reduced quality control requirements, and less buffer waste. 

Toward a More Connected Downstream Process

Real-time analytics are another part of the equation. With conventional buffer preparation, the buffer is prepared first and then sampled and tested before it is released for use. If something is wrong, the problem is discovered after the work has already been done. With inline formulation, parameters including pH and conductivity can be monitored continuously before the buffer is sent to the chromatography system. 

From a GMP standpoint, Lefebvre said, that provides better process control and traceability along with a record of what was actually delivered to the process. It also points toward a model in which quality control becomes more continuous rather than relying entirely on discrete testing after preparation. 

Looking further ahead, both Lefebvre and Shah expect integration and automation to play a larger role in how downstream facilities are designed. Lefebvre noted that the value of automation is not simply about replacing labor. Skilled operators are increasingly difficult to find, and there is value in using those people where their experience matters most rather than having them spend time preparing buffers, cleaning tanks or waiting for analytical results. At the same time, manufacturers are under pressure to get more out of expensive cleanroom space and to build facilities that can handle different products and batch sizes. 

There is also a sustainability component. Water, cleaning chemicals, buffer waste and single-use plastics all carry a cost today, but Lefebvre expects their environmental impact to play a larger role in future investment decisions. He also sees digital integration as one of the biggest changes ahead. When chromatography, buffer preparation, analytics and process control all communicate in real time, the industry begins to move beyond automated pieces of equipment toward an automated process as a whole. 

The approach will not bring the same benefit to every process. Lefebvre noted that it is particularly attractive when purification requires many different buffer formulations, such as affinity capture, and in multiproduct facilities and CDMOs where flexibility is especially important. The more complex the buffer recipes and the greater the variety, the stronger the case for being able to formulate them on demand. 

When asked how he would design a new biomanufacturing facility if he could start with a blank sheet of paper, Lefebvre said he would begin with flexibility and integration rather than large pieces of fixed infrastructure. Chromatography, buffer preparation, and analytics would not be treated as independent operations. They would be designed to communicate from the start. 

“If these systems communicate with each other, we can produce what we need, when we need, and avoid all unnecessary preparation, storage and waste,” he said. 

His final point gets to the heart of the study. 

“Don’t design around equipment,” Lefebvre said, “but design around the flow of the process, the information, and the actual and forthcoming demand.” 

That shift in thinking may ultimately be more important than any one piece of equipment. The immediate case for inline buffer formulation can be measured in floor space, operating costs and buffer savings, but the broader opportunity is connecting downstream operations so they can respond to each other. Instead of building capacity around what a process might need, facilities can increasingly use real-time information to produce what the process actually needs. 

To learn more, please see the full white paper: Transform Downstream Processing with an Integrated Solution: Optimize Time, Space and Cost Using MOTIV® Inline Buffer Formulation with FlexiPro™ Chrom.

Pin It on Pinterest